A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms IMmotion010
- Sponsors Chugai Pharmaceutical; Roche
- 04 Jun 2024 Results of an exploratory biomarker analysis assessing circulating kidney injury molecule-1 biomarker presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 08 Sep 2023 The trial has been completed in Netherlands, Germany, Denmark, Belgium, Poland, France and Spain according to European Clinical Trials Database record.
- 29 Aug 2023 The trial has been completed in Austria (End Date: 08 Dec 2022), according to European Clinical Trials Database record.